Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials

Selinexor is an oral, small molecule inhibitor of the nuclear export protein exportin 1 with demonstrated activity in hematologic and solid malignancies. Side effects associated with selinexor include nausea, vomiting, fatigue, diarrhea, decreased appetite, weight loss, thrombocytopenia, neutropenia...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Leukemia
Main Authors: Gavriatopoulou, Maria, Chari, Ajai, Chen, Christine, Bahlis, Nizar, Vogl, Dan T., Jakubowiak, Andrzej, Dingli, David, Cornell, Robert F., Hofmeister, Craig C., Siegel, David, Berdeja, Jesus G., Reece, Donna, White, Darrell, Lentzsch, Suzanne, Gasparetto, Cristina, Huff, Carol Ann, Jagannath, Sundar, Baz, Rachid, Nooka, Ajay K., Richter, Joshua, Abonour, Rafat, Parker, Terri L., Yee, Andrew J., Moreau, Philippe, Lonial, Sagar, Tuchman, Sascha, Weisel, Katja C., Mohty, Mohamad, Choquet, Sylvain, Unger, T. J., Li, Kai, Chai, Yi, Li, Lingling, Shah, Jatin, Shacham, Sharon, Kauffman, Michael G., Dimopoulos, Meletios Athanasios
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7449872/
https://ncbi.nlm.nih.gov/pubmed/32094461
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41375-020-0756-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados